aztreonam / Generic mfg. - LARVOL DELTA

Outcomes of cefepime/nacubactam and aztreonam/nacubactam in cUTI/AP patients with ESBL-producing bacteria enrolled into prospective phase III randomised clinical study (Integral-1) (ESCMID Global 2026) - No abstract available

Clinical • P3 data

Population pharmacokinetic analysis of nacubactam, cefepime, and aztreonam and exposure–response analysis of efficacy results from phase III clinical trials (ESCMID Global 2026) - No abstract available

Clinical • P3 data • PK/PD data

Efficacy and safety of cefepime/nacubactam and aztreonam/nacubactam vs best available therapy in adults with cUTI/AP, HABP/VABP, cIAI due to carbapenem resistant Enterobacterales: integral-2, single-blind, randomised phase III trial (ESCMID Global 2026) - No abstract available

Clinical • P3 data

Outcomes of cefepime/nacubactam and aztreonam/nacubactam for treatment of cUTI/AP patients with CRE: subgroup analysis of integral-1 study (ESCMID Global 2026) - No abstract available

Clinical

Efficacy and safety of cefepime/nacubactam and aztreonam/nacubactam compared with imipenem/cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis: integral-1, a double-blind, randomised phase III trial (ESCMID Global 2026) - No abstract available

Clinical • P3 data • Infectious Disease • Nephrology

Determination of the nonclinical PK/PD target value for nacubactam in a mouse thigh infection model using carbapenem-resistant Enterobacterales under co-administration of cefepime or aztreonam (ESCMID Global 2026) - No abstract available

PK/PD data • Preclinical • Infectious Disease

Probability of target attainment of cefepime/nacubactam and aztreonam/nacubactam for carbapenem-resistant Enterobacterales infections (ESCMID Global 2026) - No abstract available

Infectious Disease

Pathogen Distribution and Antimicrobial Resistance Patterns in Pediatric Lower Respiratory Tract Mycoplasma pneumoniae Pneumonia. (PubMed, APMIS) - "Among Gram-negative isolates, Klebsiella pneumoniae had the highest resistance to cefotaxime (40%), Escherichia coli to piperacillin (50%), and Pseudomonas aeruginosa to aztreonam (54%)...Staphylococcus epidermidis showed elevated resistance to clindamycin, levofloxacin, and penicillin (43% each)...Co-isolated bacterial pathogens from children with lower respiratory tract MPP show notable antimicrobial resistance. Routine pathogen testing and susceptibility profiling are crucial for guiding targeted therapy and curbing multidrug resistance."

Journal • Retrospective data • Infectious Disease • Pediatrics • Pneumococcal Infections • Pneumonia • Respiratory Diseases

FEASIBILITY AND IMPACT SIGNALS OF AN ANC-TRIGGERED PROPHYLACTIC/PRE-EMPTIVE GRANULOCYTE TRANSFUSION PROGRAM IN T-CELL REPLETE PARTIALLY MATCHED RELATED DONOR HSCT FOR HEMATOLOGICAL MALIGNANCIES: A SINGLE-CENTRE EXPERIENCE (EBMT 2026) - "Second-line escalation most commonly included meropenem (n=9), glycopeptide (teicoplanin/vancomycin; n=6), and polymyxin/colistin (n=8); one patient required escalation to ceftazidime–avibactam plus aztreonam as third-line therapy. A universal ANC-triggered prophylactic/pre-emptive granulocyte transfusion program was operationally feasible in this real-world T-cell replete PMRD HSCT cohort and was associated with zero early infection-related mortality by day +90 despite a high-risk population and frequent need for second line antibiotic escalation. This timing-focused strategy (ANC <100/µL; pre-fever/first spike) is hypothesis-generating and warrants evaluation against matched or historical controls using standardized bacteremia/AMR and infection-severity endpoints. Third line escalation was probably minimized as only 1 patient required such escalation in this limited cohort."

Clinical • Bone Marrow Transplantation • Hematological Malignancies • Infectious Disease • Myelofibrosis • Oncology

Molecular characterization & risk factors associated with carbapenemase-producing enterobacterales acquisition in hospitalised patients in a tertiary care setting. (PubMed, Indian J Med Res) - "CP-CRE isolates exhibited high resistance (70-90%) to fluoroquinolones, aztreonam, aminoglycosides, and tetracyclines, moderate resistance to tigecycline, and the lowest to colistin (2/58, 3.5%). Interpretation & conclusions This study revealed a high prevalence of CP-CRE, predominantly blaNDM-producing K. pneumoniae. CP-CRE infections were associated with multidrug resistance, increased mortality, and risk factors like prolonged hospitalisation, surgical procedures, and previous carbapenem exposure."

Journal • Infectious Disease • Pneumonia

Cefiderocol-resistant Aeromonas with expanded Resistomes in German hospital wastewater: Phenotypic and genomic evidence from the environment-clinical Interface. (PubMed, Sci Total Environ) - "Resistance phenotypes diverged markedly: cefiderocol-selected wastewater isolates exhibited high resistance rates to multiple clinically relevant agents - ciprofloxacin (93.1%), aztreonam (81.2%), and trimethoprim-sulfamethoxazole (38.9%), whereas clinical isolates remained largely susceptible overall (<10%). Notably, extensive plasmid-backbone homology was detected between Aeromonas and co-occurring cefiderocol-resistant Enterobacterales isolated from the same wastewater samples, highlighting interspecies gene flow at the hospital-environment interface. Together, these findings identify hospital wastewater as a reservoir and convergence point for highly resistant, mobilome-enriched Aeromonas subpopulations captured under cefiderocol selection, supporting Aeromonas as a One Health sentinel and emphasizing the value of wastewater-based surveillance for tracking mobile resistance determinants bridging environmental and clinical compartments."

Journal • Gene Therapies • Infectious Disease

Comparative Evaluation of Practical in-vitro Methods for Testing Synergy between Ceftazidime-Avibactam and Aztreonam against Metallo-β-lactamase and Serine Carbapenemase-producing Enterobacterales species. (PubMed, Indian J Med Microbiol) - "The combination of CZA and ATM demonstrated significant synergistic results in MBL and serine carbapenemase-producing Enterobacterales species. The disk replacement and inverse D-zone methods are feasible and cost-effective for CZA and ATM synergy testing in routine AST within resource-limited settings, guiding treatment decisions."

Journal • Preclinical

Ceftazidime/avibactam and aztreonam combined with an aminoglycoside combat metallo-β-lactamase-producing Klebsiella pneumoniae. (PubMed, Antimicrob Agents Chemother) - "Combination regimens with aminoglycosides (amikacin or plazomicin) occasionally demonstrated synergy using traditional definitions based on viable colony counting, but they were able to consistently reduce bacterial turbidity and the emergence of filamentous cells that were observed during exposure to ceftazidime/avibactam + aztreonam. Combinations between ceftazidime/avibactam, aztreonam, and an aminoglycoside are a potentially promising therapeutic strategy to combat the rising threat posed by MBL-producing K. pneumoniae."

Journal • Infectious Disease • Pneumonia

Real-world use of ceftazidime/avibactam plus aztreonam in children with MBL-producing Gram-negative infections (ESCMID Global 2026) - No abstract available

Clinical • Gram negative • Real-world • Real-world evidence • Infectious Disease

Impact of ceftazidime/avibactam plus aztreonam on mortality in metallo-β-lactamase-producing Enterobacterales bloodstream infections: a propensity score-matched analysis (ESCMID Global 2026) - No abstract available

Infectious Disease

Outcomes of MBL-producing Pseudomonas aeruginosa vs Enterobacterales bloodstream infections treated with ceftazidime/avibactam plus aztreonam: a multi-centre study, Chile, 2019–2025 (ESCMID Global 2026) - No abstract available

Clinical • Infectious Disease

Aztreonam acts as a synergist for ceftazidime/avibactam against carbapenem-resistant Enterobacteriaceae (CRE) of various carbapenemase phenotypes in Southwestern China (ESCMID Global 2026) - No abstract available

Evaluation of ceftazidime/avibactam in combination with aztreonam, meropenem and amikacin in carbapenem-resistant Klebsiella pneumoniae strains and the distribution of carbapenemase-encoding genes (ESCMID Global 2026) - No abstract available

Combination therapy • Infectious Disease • Pneumonia

Optimising synergy testing: a modified disc elution approach for aztreonam/ceftazidime/avibactam synergy testing in carbapenem-resistant Enterobacterales (ESCMID Global 2026) - No abstract available

Targeting metallo-β-lactamase endemicity: activity of novel meropenem-ANT3310 in combination with aztreonam against contemporary Enterobacterales (ESCMID Global 2026) - No abstract available

Combination therapy

Comparison of ceftazidime plus avibactam and aztreonam synergy test from positive blood culture bottles with regular disk diffusion test with culture isolates (ESCMID Global 2026) - No abstract available

Aztreonam plus ceftazidime/avibactam broth disk elution test: failure to detect Escherichia coli with PBP-3 insertions. (PubMed, Eur J Clin Microbiol Infect Dis) - "AZA MIC Test Strips can reliably predict ATM-CZA BDE results, except for strains with MICs of 4/4 µg/ml. ATM-CZA BDE failed to detect most of E. coli with PBP-3 insertions. E. coli with AZA MICs ranging from 1/4 to 4/4 µg/ml could be screened for PBP-3 insertions, and patients infected with such isolates, should be monitored for possible treatment failures with AZA or ATM-CZA."

Journal

Synergistic effects of ceftazidime/avibactam, imipenem/relebactam, meropenem/varbobactam with aztreonam, colistin or fosfomycin on metallo-β-lactamase–producing Klebsiella pneumoniae strains (ESCMID Global 2026) - No abstract available

Infectious Disease • Pneumonia

In vitro activity aztreonam and avibactam or ceftazidime/avibactam combinations against clinical Stenotrophomonas maltophilia isolates (ESCMID Global 2026) - No abstract available

Preclinical

Comparative analysis of the effects of aztreonam combined with four β-lactamase inhibitors against carbapenem-resistant Enterobacterales. (PubMed, Microbiol Spectr) - "Using microbroth dilution, checkerboard assays, and time‒kill curves, aztreonam/clavulanic acid showed potent synergy against MBL+/AmpC- strains (26/27), with MIC50/MIC90 values (≤0.12/1 µg/mL) comparable to those of aztreonam/avibactam (≤0.12/0.5 µg/mL). Additionally, the findings provide reference for reducing over-reliance on newer antibiotics like avibactam, supporting efforts to delay antimicrobial resistance. This work may be of practical use for regions with limited access to high-cost antimicrobials."

Journal • Infectious Disease • Pediatrics